New EU Filings Include Serplulimab For Lung Cancer & Zynyz For MCC

EU marketing applications for eight new products have begun the regulatory review process at the European Medicines Agency.

New medicines are under regulatory review for potential EU marketing approval • Source: Shutterstock

Serplulimab, Zynyz (retifanlimab) and danicopan are among the new products that the European Medicines Agency has begun reviewing for potential pan-EU marketing approval.

Serplulimab, from Henlius Biotech, is an anti-PD-1 monoclonal antibody (mAb) for use in combination with chemotherapy (carboplatin and etoposide) for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet